JP2023532736A - 血液脳関門を通過する薬物送達のための化合物 - Google Patents

血液脳関門を通過する薬物送達のための化合物 Download PDF

Info

Publication number
JP2023532736A
JP2023532736A JP2022581583A JP2022581583A JP2023532736A JP 2023532736 A JP2023532736 A JP 2023532736A JP 2022581583 A JP2022581583 A JP 2022581583A JP 2022581583 A JP2022581583 A JP 2022581583A JP 2023532736 A JP2023532736 A JP 2023532736A
Authority
JP
Japan
Prior art keywords
beads
cells
trbp6
compounds
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581583A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022005807A5 (https=
JP2023532736A5 (https=
Inventor
グオ，ビン
ゴミカ ウドゥガマスーリヤ，ダミス
リウ，シンリー
プラカシュ シュクラ，サトヤ
チョ，クァンボク
ジョウ，シュエ
Original Assignee
ユニバーシティー オブ ヒューストン システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ ヒューストン システム filed Critical ユニバーシティー オブ ヒューストン システム
Publication of JP2023532736A publication Critical patent/JP2023532736A/ja
Publication of JPWO2022005807A5 publication Critical patent/JPWO2022005807A5/ja
Publication of JP2023532736A5 publication Critical patent/JP2023532736A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022581583A 2020-07-02 2021-06-22 血液脳関門を通過する薬物送達のための化合物 Pending JP2023532736A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047440P 2020-07-02 2020-07-02
US63/047,440 2020-07-02
PCT/US2021/038408 WO2022005807A1 (en) 2020-07-02 2021-06-22 Compounds for drug delivery across blood-brain barrier

Publications (3)

Publication Number Publication Date
JP2023532736A true JP2023532736A (ja) 2023-07-31
JPWO2022005807A5 JPWO2022005807A5 (https=) 2024-06-27
JP2023532736A5 JP2023532736A5 (https=) 2024-06-27

Family

ID=77317394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581583A Pending JP2023532736A (ja) 2020-07-02 2021-06-22 血液脳関門を通過する薬物送達のための化合物

Country Status (5)

Country Link
US (1) US20230257420A1 (https=)
EP (1) EP4175715A1 (https=)
JP (1) JP2023532736A (https=)
CA (1) CA3184089A1 (https=)
WO (1) WO2022005807A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049772A2 (en) * 2001-12-11 2003-06-19 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
WO2017015644A1 (en) * 2015-07-23 2017-01-26 University Of Houston System Cancer specific lipid targeted peptidomimetics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180156826A1 (en) * 2015-06-08 2018-06-07 The Board Of Regents Of The University Of Texas Sy Stem Compositions and methods for diagnosis of autism spectrum disorder

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049772A2 (en) * 2001-12-11 2003-06-19 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
WO2017015644A1 (en) * 2015-07-23 2017-01-26 University Of Houston System Cancer specific lipid targeted peptidomimetics

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACS CHEMICAL NEUROSCIENCE, vol. 10, no. 3, JPN6025031784, 2019, pages 1355 - 1368, ISSN: 0005781314 *
BIOORGANIC, vol. 16, no. 11, JPN6025031781, 2008, pages 5853 - 5861, ISSN: 0005781311 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 95, no. 4, JPN6025031783, 1998, pages 1517 - 1522, ISSN: 0005781313 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 24, JPN6025031782, 2000, pages 13003 - 13008, ISSN: 0005781312 *

Also Published As

Publication number Publication date
EP4175715A1 (en) 2023-05-10
US20230257420A1 (en) 2023-08-17
WO2022005807A1 (en) 2022-01-06
CA3184089A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
TW202330013A (zh) 介白素－２３受體之脂化肽抑制劑
TW202332683A (zh) 介白素－２３受體之肽抑制劑
ES2349743T3 (es) Derivados de la il-21.
US20240165245A1 (en) Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same
PL185762B1 (pl) Nowe peptydy stanowiące pochodne dolastatyny, ichzastosowanie w medycynie oraz kompozycja farmaceutyczna
CN102177174B (zh) 用于靶向凋亡细胞的肽及其用途
CN101538313A (zh) 肽基化合物
US11414455B2 (en) Toll-like receptor 2 ligands and methods of making and using thereof
CN113604214B (zh) 一种高稳定性溶瘤肽荧光探针及其制备方法和应用
JP4617296B2 (ja) タンパク質結合性のドキソルビシン−ペプチド−誘導体
WO2011156003A2 (en) Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
KR102436012B1 (ko) 항암제 프로드러그 컨쥬게이트의 새로운 용도
JP6952320B2 (ja) 新規ｎｋ３受容体アゴニスト
JP2025514805A (ja) 化合物及び使用
US20020173468A1 (en) Modified cytostatic agents
JP2023532736A (ja) 血液脳関門を通過する薬物送達のための化合物
ZA200503600B (en) Peptide gap junction modulators
WO2025189832A1 (zh) 一种抗肿瘤化合物及其制备方法和应用
CN115572320B (zh) 一种前列腺癌分子探针及其制备方法与应用
JP2004531493A (ja) メタロマトリックスプロテイナーゼによって活性化される腫瘍ターゲティング・プロドラッグ
US20110237499A1 (en) Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses
JP2004501106A (ja) アミノ薬物の複合体
CN100365014C (zh) 肿瘤靶向剂及其应用
US20240083949A1 (en) Cell penetrating peptide compositions and methods thereof
JP2006518702A (ja) 腫瘍標的化剤及びその使用

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127